Sotac Pharmaceuticals
- P/E
- 32.24
Key Fundamentals
SMEPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · TTM
- ROCE
- 12.50%
- Debt to Equity
- 0.64
- EPS (TTM)
- ₹4.00
- Book Value
- ₹53.28
- Market Cap
- —
- P/E (TTM)
- 32.24
- P/B
- 2.42
- ROE
- 10.10%
- Dividend Yield
- 0.16%
- EBITDA
- ₹18.20 Cr
- 52W High
- ₹139.65
- 52W Low
- ₹86.00
- Day Range
- ₹128.95 – ₹128.95
- Volume
- 6,000
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr | |
| ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr | |
| ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr | |
| ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr | |
| ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr | |
| ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr | |
| ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr | |
| Sotac Pharmaceuticals (this company) | ₹128.95 | 32.24 | ₹142 Cr | 2.42 | 0.16% | 10.10% | 12.50% | ₹106 Cr | ₹5 Cr |
| Median 8 companies | ₹1,587.70 | 37.20 | ₹1,25,337 Cr | 4.57 | 0.44% | 16.25% | 16.65% | ₹22,862 Cr | ₹3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Key Insights
Strengths
1- Company has delivered good profit growth of 34.5% CAGR over last 5 years
Weaknesses
1- Company has a low return on equity of 12.8% over last 3 years.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bullish | 5 | 2 | 12 |
| Oscillators | Strong Bearish | 5 | 2 | 2 |
| Moving Averages | Strong Bullish | 0 | 0 | 10 |
Oscillators
Strong Bearish
Overall
Strong Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 75.45
- Bearish
- MACD (12,26,9)
- 3.38
- Bullish
- SMA (50)
- 106.13
- Bullish
- SMA (200)
- 116.51
- Bullish
As of
Growth Rate
From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025.
Revenue
| 5Y | +15.56% |
|---|---|
| 3Y | +9.47% |
| 1Y | +1.00% |
Net profit
| 5Y | Turned to profit |
|---|---|
| 3Y | +44.22% |
| 1Y | −33.33% |
Operating cash flow
| 5Y | Zero base |
|---|---|
| 3Y | +28.56% |
| 1Y | Turned positive |
Operating margin· change in pp
| 5Y | +15.78 pp |
|---|---|
| 3Y | +8.73 pp |
| 1Y | +1.82 pp |
Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.
Revenue by year
| Mar 2020 | ₹29.00 Cr |
|---|---|
| Mar 2021 | ₹49.00 Cr |
| Mar 2023 | ₹77.00 Cr |
| Mar 2024 | ₹104 Cr |
| Mar 2025 | ₹100 Cr |
| Mar 2026 | ₹101 Cr |
Net profit by year
| Mar 2020 | ₹0.00 Cr |
|---|---|
| Mar 2021 | −₹2.00 Cr |
| Mar 2023 | ₹2.00 Cr |
| Mar 2024 | ₹4.00 Cr |
| Mar 2025 | ₹9.00 Cr |
| Mar 2026 | ₹6.00 Cr |
Half-yearly Results
₹ Cr| Particulars | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 40 | 38 | 52 | 52 | 53 | 47 | 37 | 60 |
| Expenses | 36 | 34 | 47 | 48 | 48 | 35 | 33 | 50 |
| Operating Profit | 3 | 4 | 4 | 4 | 4 | 12 | 4 | 10 |
| OPM % | 9% | 10% | 9% | 8% | 8% | 26% | 10% | 17% |
| Other Income | 1 | 0 | 0 | 0 | 1 | 0 | 4 | 0 |
| Interest | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
| Depreciation | 1 | 1 | 1 | 2 | 1 | 2 | 3 | 3 |
| PBT | 2 | 2 | 2 | 2 | 3 | 9 | 3 | 5 |
| Tax % | 49% | 34% | 45% | −34% | 30% | 13% | 23% | 31% |
| Net Profit | 2 | 1 | 2 | 3 | 2 | 6 | 2 | 3 |
| EPS (₹) | 1.93 | 1.64 | 1.57 | 2.31 | 1.73 | 5.53 | 2.22 | 3 |
Profit & Loss
₹ Cr| Particulars | Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Sales | 29 | 49 | 77 | 104 | 100 | 101 |
| Expenses | 27 | 47 | 70 | 95 | 83 | 83 |
| Operating Profit | 2 | 1 | 7 | 9 | 16 | 18 |
| OPM % | 7% | 3% | 10% | 8% | 16% | 18% |
| Other Income | 0 | 0 | 1 | 0 | 1 | 0 |
| Interest | 0 | 1 | 2 | 2 | 3 | 4 |
| Depreciation | 1 | 3 | 2 | 3 | 4 | 5 |
| PBT | 0 | −2 | 4 | 4 | 11 | 9 |
| Tax % | 75% | 15% | 42% | 10% | 17% | 28% |
| Net Profit | 0 | −2 | 2 | 4 | 9 | 6 |
| EPS (₹) | 0.11 | −2.93 | 3.58 | 3.87 | 7.27 | 5.22 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 4% |
Balance Sheet
₹ Cr| Particulars | Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 8 | 11 | 11 | 11 |
| Reserves | 1 | 0 | 11 | 34 | 42 | 48 |
| Borrowings | 13 | 17 | 22 | 25 | 44 | 38 |
| Other Liabilities | 14 | 15 | 32 | 35 | 27 | 37 |
| Total Liabilities | 30 | 35 | 74 | 105 | 124 | 133 |
| Fixed Assets | 16 | 17 | 26 | 36 | 49 | 50 |
| CWIP | 0 | 0 | 0 | 5 | 0 | 2 |
| Investments | 0 | 0 | 0 | 2 | 4 | 3 |
| Other Assets | 14 | 18 | 48 | 63 | 72 | 79 |
| Total Assets | 30 | 35 | 74 | 105 | 124 | 133 |
Cash Flow
₹ Cr| Particulars | Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Operating | 0 | 0 | 8 | −16 | −4 | 17 |
| Investing | −12 | −3 | −12 | −20 | −14 | −7 |
| Financing | 11 | 3 | 13 | 29 | 16 | −10 |
| Net Cash Flow | 0 | 0 | 10 | −6 | −2 | 0 |
| Free Cash Flow | −10 | −3 | 0 | −34 | −16 | 9 |
| CFO/EBITDA | 17 | 8 | 134 | −168 | −22 | 106 |
Ratios
| Particulars | Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor Days | 89 | 44 | 70 | 92 | 125 | 119 |
| Inventory Days | 40 | 45 | 87 | 83 | 108 | 153 |
| Days Payable | 194 | 121 | 162 | 132 | 101 | 154 |
| Cash Conversion Cycle | −66 | −32 | −5 | 43 | 132 | 119 |
| Working Capital Days | −79 | −44 | −40 | 47 | 61 | 66 |
| ROCE % | — | −5% | — | 10% | 15% | 12% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Sotac Pharmaceuticals insights
55 extracted metrics across FY20–FY26.
Documents
- 12 Oct 2026
- 8 Oct 2026
- 8 Oct 2026
- 1 Oct 2026
Frequently Asked Questions about Sotac Pharmaceuticals
What does Sotac Pharmaceuticals Ltd do?
Where is Sotac Pharmaceuticals Ltd (SOTAC) listed?
Which sector does Sotac Pharmaceuticals Ltd belong to?
What is the PE ratio of Sotac Pharmaceuticals Ltd?
What is the 52-week high and low of Sotac Pharmaceuticals Ltd?
Does Sotac Pharmaceuticals Ltd pay dividends?
What is the Return on Equity (ROE) of Sotac Pharmaceuticals Ltd?
Company Information
Incorporated in 2015, Sotac Pharmaceuticals Ltd manufactures and sells a wide range of pharmaceutical products
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/SOTAC.md for Sotac Pharmaceuticals Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.